

Application No.: 09/623,543

2

Docket No.: 500862002200

AMENDMENTS TO THE CLAIMS

Claims 1 -21 (Cancelled)

Claim 22 (Currently amended): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide wherein said kringle 5 peptide comprises SEQ ID NO:8 and a reactive group coupled thereto, ~~to said kringle 5 peptide~~ said reactive group reacting with an amino group, a hydroxyl group, or a thiol group on a blood component to form a stable covalent bond, wherein said reactive group is a succinimidyl-containing group or a maleimido-containing group.

Claim 23 (Cancelled)

Claim 24 (Previously presented): The method of claim 22, wherein said blood component is a blood protein.

Claim 25 (Previously presented): The method of claim 22, wherein said modified peptide is reactive with a thiol group on a blood protein.

Claim 26 (Cancelled)

Claim 27 (Cancelled)

Claim 28 (Previously presented): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide comprising a kringle 5 peptide with a maleimido group coupled thereto, said maleimido group reacting with a thiol group on human serum albumin to form a stable covalent bond wherein said kringle 5 peptide comprises SEQ ID NO: 8.

Claim 29 - 32 (Cancelled)

sf-2084049

Application No.: 09/623,543

3

Docket No.: 500862002200

Claim 33 (Allowed): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide of the sequence (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO: 39).

Claim 34 (Currently amended): A method of using a modified kringle 5 peptide wherein said kringle 5 peptide comprises SEQ ID NO: 8 and a maleimido group coupled to said kringle 5 peptide wherein said maleimido group reacts with a thiol group on a blood protein to form a covalent bond, for manufacturing an anti-angiogenic medicament ~~having an extended in vivo half life compared to said kringle 5 peptide in the absence of said maleimido group.~~

Claim 35 (Currently amended): A conjugate comprising of formula:

~~blood component reactive group peptide,~~

wherein said peptide is a modified kringle 5 peptide covalently bonded to a blood component, where said modified kringle 5 peptide comprises a kringle 5 peptide comprising SEQ ID NO:8 and a reactive group coupled thereto, and wherein said reactive group is bonded to an
reacts with an amino group, a hydroxyl group, or a thiol group of said on said blood component by
means of to form a stable covalent bond, and wherein said reactive group being is a succinimidyl-
containing or a maleimido-containing group.

Claim 36 (Previously presented): The conjugate of claim 35, wherein said blood component is a blood protein.

Claim 37 (Cancelled)

sf-2084049

Application No.: 09/623,543

4

Docket No.: 500862002200

Claim 38 (Previously presented): The conjugate of claim 36, wherein said reactive group is covalently bonded to a thiol group on said blood protein.

Claim 39 (Cancelled)

Claim 40 (Cancelled)

Claim 41 (Previously presented): The conjugate of claim 36, wherein said blood protein is serum albumin.

Claim 42 (Currently amended): A composition for providing an anti-angiogenic effect to a patient, comprising a conjugate of claim 35 in association with a pharmaceutically acceptable carrier.

Claim 43 (Previously presented): The composition of claim 42, wherein said blood component is a blood protein.

Claim 44 (Cancelled)

Claim 45 (Previously presented): The composition of claim 42, wherein said reactive group is covalently bonded to a thiol group on said blood protein.

Claim 46 (Cancelled)

Claim 47 (Cancelled)

Claim 48 (Previously presented): The composition of claim 42, wherein said blood protein is serum albumin.

sf-2084049

Application No.: 09/623,543

5

Docket No.: 500862002200

Claim 49 (New): A conjugate comprising a modified kringle 5 peptide covalently bonded to albumin, where said modified kringle 5 peptide comprises SEQ ID NO: 8 and a reactive group coupled thereto, wherein said reactive group reacts with an amino group, a hydroxyl group or a thiol group on albumin to form stable covalent bond, and wherein said reactive group is a succinimidyl-containing and maleimido-containing group.

Claim 50 (New): The method of claim 22 wherein said reactive group is a succinimidyl-containing group.

Claim 51 (New): The method of claim 22 wherein said reactive group is a maleimido-containing group.

Claim 52 (New): The conjugate of claim 35 wherein said reactive group is a succinimidyl-containing group.

Claim 53 (New): The conjugate of claim 35 wherein said reactive group is a maleimido-containing group.

Claim 54 (New): The conjugate of claim 49, wherein said reactive group is a succinimidyl-containing group.

Claim 55 (New): The conjugate of claim 49, wherein said reactive group is a maleimido-containing group.

sf-2084049